Vistagen Therapeutics (VTGN) EBITDA Margin (2017 - 2025)
Historic EBITDA Margin for Vistagen Therapeutics (VTGN) over the last 11 years, with Q4 2025 value amounting to 6237.62%.
- Vistagen Therapeutics' EBITDA Margin fell 2119800.0% to 6237.62% in Q4 2025 from the same period last year, while for Dec 2025 it was 8486.58%, marking a year-over-year decrease of 13748500.0%. This contributed to the annual value of 10578.81% for FY2025, which is 78192200.0% down from last year.
- Latest data reveals that Vistagen Therapeutics reported EBITDA Margin of 6237.62% as of Q4 2025, which was down 2119800.0% from 7520.93% recorded in Q3 2025.
- In the past 5 years, Vistagen Therapeutics' EBITDA Margin ranged from a high of 90940.0% in Q1 2025 and a low of 42802.56% during Q1 2022
- For the 5-year period, Vistagen Therapeutics' EBITDA Margin averaged around 2075.44%, with its median value being 5615.66% (2022).
- In the last 5 years, Vistagen Therapeutics' EBITDA Margin plummeted by -413955500bps in 2022 and then surged by 967454900bps in 2025.
- Vistagen Therapeutics' EBITDA Margin (Quarter) stood at 2943.85% in 2021, then plummeted by -84bps to 5425.83% in 2022, then surged by 72bps to 1545.01% in 2023, then crashed by -290bps to 6025.64% in 2024, then fell by -4bps to 6237.62% in 2025.
- Its last three reported values are 6237.62% in Q4 2025, 7520.93% for Q3 2025, and 6188.11% during Q2 2025.